WO2004053094A3 - Compositions and methods for inhibiting human immunodeficiency virus infection by down-regulating human cellular genes - Google Patents

Compositions and methods for inhibiting human immunodeficiency virus infection by down-regulating human cellular genes Download PDF

Info

Publication number
WO2004053094A3
WO2004053094A3 PCT/US2003/039208 US0339208W WO2004053094A3 WO 2004053094 A3 WO2004053094 A3 WO 2004053094A3 US 0339208 W US0339208 W US 0339208W WO 2004053094 A3 WO2004053094 A3 WO 2004053094A3
Authority
WO
WIPO (PCT)
Prior art keywords
immunodeficiency virus
methods
compositions
cellular genes
virus infection
Prior art date
Application number
PCT/US2003/039208
Other languages
French (fr)
Other versions
WO2004053094A2 (en
Inventor
Stephen J Dunn
Tanya A Di Holzmayer
Original Assignee
Ppd Dev Lp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ppd Dev Lp filed Critical Ppd Dev Lp
Priority to AU2003297809A priority Critical patent/AU2003297809A1/en
Publication of WO2004053094A2 publication Critical patent/WO2004053094A2/en
Publication of WO2004053094A3 publication Critical patent/WO2004053094A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7153—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for colony-stimulating factors [CSF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/7056—Lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7158—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for chemokines

Abstract

The invention provides methods for identifiying human cellular genes and their encoded products for use as targets in the design of therapeutic agents for inhibiting or suppressing human immunodeficiency virus (HIV) infection. The invention also provides methods for identifying protective compounds including immunizing agents that inhibit HIV infection. The invention further provides compounds for use in the treatment or prevention of HIV.
PCT/US2003/039208 2002-12-06 2003-12-08 Compositions and methods for inhibiting human immunodeficiency virus infection by down-regulating human cellular genes WO2004053094A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003297809A AU2003297809A1 (en) 2002-12-06 2003-12-08 Compositions and methods for inhibiting human immunodeficiency virus infection by down-regulating human cellular genes

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43152202P 2002-12-06 2002-12-06
US60/431,522 2002-12-06

Publications (2)

Publication Number Publication Date
WO2004053094A2 WO2004053094A2 (en) 2004-06-24
WO2004053094A3 true WO2004053094A3 (en) 2004-09-16

Family

ID=32507745

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/039208 WO2004053094A2 (en) 2002-12-06 2003-12-08 Compositions and methods for inhibiting human immunodeficiency virus infection by down-regulating human cellular genes

Country Status (2)

Country Link
AU (1) AU2003297809A1 (en)
WO (1) WO2004053094A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2903998B1 (en) * 2006-07-19 2008-09-05 Galderma Res & Dev S N C Snc MODULATORS OF ELOVL5 IN THE TREATMENT OF ACNE OR HYPERSEBORRHEA
US20120065084A1 (en) * 2009-04-17 2012-03-15 Universite Libre De Bruxelles Methods and tools for predicting the efficiency of anthracyclines in cancer

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5217889A (en) * 1990-10-19 1993-06-08 Roninson Igor B Methods and applications for efficient genetic suppressor elements
US5256534A (en) * 1991-08-09 1993-10-26 The United States Of America As Represented By The Department Of Health And Human Services CD4+, latently HIV-1-infected hematopoietic progenitor cells

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5217889A (en) * 1990-10-19 1993-06-08 Roninson Igor B Methods and applications for efficient genetic suppressor elements
US5256534A (en) * 1991-08-09 1993-10-26 The United States Of America As Represented By The Department Of Health And Human Services CD4+, latently HIV-1-infected hematopoietic progenitor cells

Also Published As

Publication number Publication date
WO2004053094A2 (en) 2004-06-24
AU2003297809A8 (en) 2004-06-30
AU2003297809A1 (en) 2004-06-30

Similar Documents

Publication Publication Date Title
WO2004006858A3 (en) Compounds, compositions, and methods employing same
WO2004062625A3 (en) Macrocyclic beta-secretase inhibitors for treatment of alzheimer's disease
WO2005018555A3 (en) Lipid-modified immune response modifiers
WO2005004803A3 (en) Phenylcarboxylate beta-secretase inhibitors for the treatment of alzheimer's disease
WO2004073623A3 (en) Treatment of conditions associated with decreased nitric oxide bioavailability, including elevated arginase conditions
WO2006024018A3 (en) Compositions for treating nociceptive pain
WO2009055006A8 (en) Deuterated darunavir
WO2005018545A3 (en) Macrocyclic beta-secretase inhibitors for the treatment of alzheimer's disease
WO2004100881A3 (en) Preparation and use of aryl alkyl acid derivatives for the treatment of obesity
WO2005079195A3 (en) Pyrazolopyridines and analogs thereof
NO20062767L (en) immunoglobulins
WO2002102981A3 (en) SIR2α-BASED THERAPEUTIC AND PROPHYLACTIC METHODS
WO2004009610A3 (en) Use of nucleoside compounds for nonsense suppression and the treatment of genetic diseases
TW200510343A (en) Substituted dihydroquinazolines
ATE506959T1 (en) USE OF IL-18 INHIBITORS
WO2004043456A8 (en) Cholesterol absorption inhibitors for the treatment of demyelination
WO2002079169A8 (en) Cyano-substituted dihydropyrimidine compounds and their use to treat diseases
WO2002094189A3 (en) Compositions and methods for treating or preventing convulsions or seizures
WO2006137938A3 (en) Antibody fragments for protection from pathogen infection and methods of use thereof
WO2003002528A3 (en) Compositions and methods for inhibiting human immunodeficiency virus infection by down-regulating human cellular genes
EP1336619A3 (en) Combination of a HVEM-LIGHT inhibitor and an immunosuppressive agent in the treatment or prevention of immune disorders
WO2005046587A3 (en) Preparation and composition of inter-alpha inhibitor proteins from human plasma for therapeutic use
WO2004073615A3 (en) Deazaflavin compounds and methods of use thereof
WO2004030631A3 (en) Anti-cancer and anti-infectious disease compositions and methods for using same
WO2004110373A3 (en) Therapeutic vaccine compositions for the treatment of type 1 diabetes

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP